News
ORIC
8.92
-3.36%
-0.31
Weekly Report: what happened at ORIC last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at ORIC last week (1026-1030)?
Weekly Report · 11/02 09:05
Stifel Nicolaus Sticks to Their Buy Rating for Oric Pharmaceuticals (ORIC)
TipRanks · 10/30 02:16
Oric Pharmaceuticals Price Target Maintained With a $26.00/Share by BTIG
Dow Jones · 10/28 10:08
BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price Target
Benzinga · 10/28 09:58
Oric Pharmaceuticals (ORIC) Receives a Buy from Wedbush
TipRanks · 10/27 13:36
Oric Pharmaceuticals Is Maintained at Outperform by Wedbush
Dow Jones · 10/27 13:31
Oric Pharmaceuticals Price Target Cut to $14.00/Share From $17.00 by Wedbush
Dow Jones · 10/27 13:31
Wedbush Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $14
Benzinga · 10/27 13:21
Boris Peaker Reiterates Buy on ORIC, Sees Compelling Risk-Reward with Unchanged $25 Price Target
TipRanks · 10/27 12:45
Oric Pharmaceuticals price target lowered to $14 from $17 at Wedbush
TipRanks · 10/27 12:06
Oric Pharmaceuticals selloff on J&J data ‘way overdone,’ says Cantor Fitzgerald
TipRanks · 10/27 11:40
Analyst Reiterates Buy on ORIC Pharmaceuticals, Citing Best-in-Class Potential for Enozertinib and Maintaining $27 Price Target
TipRanks · 10/27 11:27
Oric Pharmaceuticals selloff brings buying opportunity, says Jones
TipRanks · 10/27 11:11
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 10/26 17:05
Oric Pharmaceuticals Is Maintained at Buy by Stifel
Dow Jones · 10/26 16:55
Stifel Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $18
Benzinga · 10/26 16:44
Oric Pharmaceuticals drops after J&J presents prostate cancer drug data
TipRanks · 10/26 15:10
Oric Pharmaceuticals price target raised to $18 from $14 at Stifel
TipRanks · 10/26 11:26
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Oric Pharmaceuticals (ORIC)
TipRanks · 10/26 09:50
More
Webull provides a variety of real-time ORIC stock news. You can receive the latest news about Oric Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.